Tech Company Financing Transactions

Solstice Biologics Funding Round

Solstice Biologics closed a $18 million Series A funding round on 1/5/2013. Investors included venBio and Aeris Capital AG.

Transaction Overview

Company Name
Announced On
1/5/2013
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors

venBio (Lead Investor) (Corey Goodman)

Aeris Capital AG (George Rehm)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1700 Owens St. 595
San Francisco, CA 94158
USA
Website
Email Address
Not Recorded
Overview
Solstice Biologics is a private company focused on solving the problem of targeting and delivery of nucleic acid therapeutics. The company is developing small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.
Profile
Solstice Biologics LinkedIn Company Profile
Social Media
Solstice Biologics Company Twitter Account
Company News
Solstice Biologics News
Facebook
Solstice Biologics on Facebook
YouTube
Solstice Biologics on YouTube

Management Team

Title
Name
Email & Social
Founder
Steven Dowdy
  Steven Dowdy LinkedIn Profile  Steven Dowdy Twitter Account  Steven Dowdy News  Steven Dowdy on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/4/2013: EndoChoice venture capital transaction
Next: 1/5/2013: Vobi venture capital transaction

 

Share this article

 


News on VC Transactions

We report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary